Skip to content
Home/Companies/Biotech/Code Biotherapeutics
Code Biotherapeutics

Code Biotherapeutics

Biotech·US·Active·4yr hold
Entry
2022
Hold
4yr
Status
Active

Who owns Code Biotherapeutics?

Code Biotherapeutics is currently owned by 4Bio Partners through 4BIO Ventures III (2022 vintage), since 2022.

Hand-verified · updated 2026-05-21

4Bio Partners
Investor
4Bio Partners
4BIO Ventures III · 2022 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive
Websitewww.codebiotx.com

More from 4BIO Ventures III

Other portfolio companies in the same fund.

Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
Actithera
Actithera
Active
BiotechSwitzerland· 2025
Hornet Therapeutics
Active
BiotechUK· 2024
March Biosciences
March Biosciences
Active
BiotechUS· 2024
Ascend Advanced Therapies
Ascend Advanced Therapies
Active
BiotechUK· 2023
Trogenix
Trogenix
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Code Biotherapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Code Biotherapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Code Biotherapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue